Cervical Intraepithelial Neoplasia Market is segmented By Current Treatment (HPV Vaccination, Surgical Excision, Ablation Therapy), By Emerging Therapies (Gene Therapy, T ....
Market Size in USD
CAGR5.2%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.2% |
Market Concentration | High |
Major Players | Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Johnson & Johnson Private Limited, Merck & Co., Inc. |
The Global Cervical Intraepithelial Neoplasia Market is estimated to be valued at USD 670.1 Mn in 2024 and is expected to reach USD 971.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
The market is expected to witness positive growth over the forecast period owing to the rising prevalence of cervical cancer worldwide. Increasing awareness among women population regarding early cancer detection through screening and vaccination programs is also contributing to the growth of the market. Various government initiatives and programs targeted towards screening women population are further supporting market expansion. Other factors such as new product launches, rising healthcare expenditure and improving healthcare infrastructure in developing nations will provide numerous growth opportunities in the cervical intraepithelial neoplasia market during the projected years.